A Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSS11 Administered Intravenously in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Pegadricase (Primary)
- Indications Gout; Tumour lysis syndrome
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
- 12 Sep 2018 Planned End Date changed from 31 Dec 2018 to 31 Jan 2020.
- 12 Sep 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jul 2019.
- 31 Aug 2018 Biomarkers information updated